Cargando…
Pirfenidone Inhibits Hypoxic Pulmonary Hypertension through the NADPH/ROS/p38 Pathway in Adventitial Fibroblasts in the Pulmonary Artery
Hypoxic pulmonary hypertension (HPH) is a devastating disease characterized by progressive vasoconstriction and vascular remodeling. Pirfenidone (PFD) inhibits the progression of HPH, though the molecular mechanisms remain unknown. This study is aimed at determining the role and mechanism of PFD in...
Autores principales: | Zhang, Song, Yin, ZongXiu, Qin, WeiDong, Ma, XiaoLi, Zhang, Yao, Liu, EnXiu, Chu, YanBiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305537/ https://www.ncbi.nlm.nih.gov/pubmed/32587469 http://dx.doi.org/10.1155/2020/2604967 |
Ejemplares similares
-
Bmi-1 alleviates adventitial fibroblast senescence by eliminating ROS in pulmonary hypertension
por: Li, Kai, et al.
Publicado: (2021) -
Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
por: Zhang, Xiu-Li, et al.
Publicado: (2023) -
Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011) -
Role of pirfenidone in the management of pulmonary fibrosis
por: Meyer, Keith C, et al.
Publicado: (2017) -
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)